DUBLIN–(BUSINESS WIRE)–The “Global
Central Nervous System Partnering 2014-2019: Deal trends, players and
financials” report has been added to ResearchAndMarkets.com’s
offering.
This report provides the full collection of Central Nervous System
disease deals signed between the world’s pharmaceutical and
biotechnology companies since 2014.
- Trends in Central Nervous System partnering deals
-
Financial deal terms for headline, upfront and royalty by stage of
development - Central Nervous System partnering agreement structure
- Central Nervous System partnering contract documents
- Top Central Nervous System deals by value
- Most active Central Nervous System dealmakers
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Central Nervous
System disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently
entering Central Nervous System deals.
The report presents financial deal terms values for Central Nervous
System deals, where available listing by overall headline values,
upfront payments, milestones and royalties enabling readers to analyse
and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Central
Nervous System dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Central Nervous System
dealmaking since 2014 covering trends by year, deal type, stage of
development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline
value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Central Nervous System deals
since 2014. Deals are listed by headline value. The chapter includes the
top 25 most active Central Nervous System dealmakers, together with a
full listing of deals to which they are a party. Where the deal has an
agreement contract published at the SEC a link provides online access to
the contract.
Chapter 5 provides comprehensive access to Central Nervous System deals
since 2014 where a deal contract is available, providing the user with
direct access to contracts as filed with the SEC regulatory authorities.
Each deal title links via Weblink to an online version of the deal
record contract document, providing easy access to each contract
document on demand.
Chapter 6 provides a comprehensive directory of all Central Nervous
System partnering deals by specific Central Nervous System target
announced since 2014. The chapter is organized by specific Central
Nervous System therapeutic target. Each deal title links via Weblink to
an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of
all Central Nervous System partnering deals signed and announced since
2014. The appendices are organized by company A-Z, stage of development
at signing, deal type (collaborative R&D, co-promotion, licensing etc)
and technology type. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in Central Nervous System partnering and
dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Central Nervous System technologies and products.
Report Scope
The report is intended to provide the reader with an in-depth
understanding and access to Central Nervous System trends and structure
of deals entered into by leading companies worldwide.
The report includes:
-
Trends in Central Nervous System dealmaking in the biopharma industry
since 2014 - Analysis of Central Nervous System deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Central Nervous System deal contract documents
- Comprehensive access to over 3500 Central Nervous System deal records
- The leading Central Nervous System deals by value since 2014
- Most active Central Nervous System dealmakers since 2014
The report includes deals for the following indications: Cerebral palsy,
Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain
Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal,
Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae
Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral
Sclerosis/Lou Gehrig’s Disease, Multiple sclerosis, Nausea, Neuropathy,
Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson’s disease, Restless
leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury,
Vertigo, Weakness, plus other CNS indications.
In the report, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
The report provides comprehensive access to available deals and contract
documents for over 1,500 central nervous system deals.
Analyzing actual contract agreements allows assessment of the
following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sub-licensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
-
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Central Nervous System dealmaking
2.1. Introduction
2.2. Central Nervous System partnering over the years
2.3. Central Nervous System partnering by deal type
2.4. Central Nervous System partnering by industry sector
2.5. Central Nervous System partnering by stage of development
2.6. Central Nervous System partnering by technology type
2.7. Central Nervous System partnering by therapeutic indication
Chapter 3 – Financial deal terms for Central Nervous System
partnering
3.1. Introduction
3.2. Disclosed financials terms for Central Nervous System partnering
3.3. Central Nervous System partnering headline values
3.4. Central Nervous System deal upfront payments
3.5. Central Nervous System deal milestone payments
3.6. Central Nervous System royalty rates
Chapter 4 – Leading Central Nervous System deals and dealmakers
4.1. Introduction
4.2. Most active in Central Nervous System partnering
4.3. List of most active dealmakers in Central Nervous System
4.4. Top Central Nervous System deals by value
Chapter 5 – Central Nervous System contract document directory
5.1. Introduction
5.2. Central Nervous System partnering deals where contract document
available
Chapter 6 – Central Nervous System dealmaking by therapeutic
target
6.1. Introduction
6.2. Deals by Central Nervous System therapeutic target
Appendices
Appendix 1 – Directory of Central Nervous System deals by company A-Z
2014 to 2019
Appendix 2 – Directory of Central Nervous System deals by deal type 2014
to 2019
Appendix 3 – Directory of Central Nervous System deals by stage of
development 2014 to 2019
Appendix 4 – Directory of Central Nervous System deals by technology
type 2014 to 2019
For more information about this report visit https://www.researchandmarkets.com/r/vj1sim
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs